The US Food and Drug Administration (FDA) has granted de novo marketing authorization for the InVitae Common Hereditary Cancers Panel to identify genetic predisposition for multiple cancers.
The cancer panel is an in vitro diagnostic test that analyses 47 genes associated with cancers of the breast, ovary, uterus, prostate, and gastrointestinal system. It can also help individuals with already-diagnosed cancer by identifying potentially cancer-associated hereditary variants.
